Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk of Distant Breast Cancer Recurrence

Genomic grade assay vs Ki67

The Genomic Grade (GG) assay can refine the prediction of risk of distant recurrence and identify a larger proportion of patients who had excellent distant recurrence-free interval (DRFI) at 10 years with just 5 years of endocrine therapy compared with centrally reviewed immunohistochemical testing of Ki67 and HG. This according to a phase 3 adjuvant trial and 883 breast cancer samples. Researchers determined:

• Either increasing GG or Ki67 was significantly associated with lower distant relapse free intervals and added independent prognostic information to standard clinicopathological factors.

• In node-negative, endocrine-only patients, low GG assay results were associated with a 10-year distant relapse-free interval of 99%.

• The GG assay can be used to identify patients with early breast cancer who have excellent prognosis for endocrine therapy only.

Citation: Ignatiadis M, Azim HA, Desmedt C, et al. The genomic grade assay compared with Ki67 to determine risk of distant breast cancer recurrence. [Published online ahead of print December 3, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.4377.